Stoke Therapeutics Announces Landmark New Data That Support

– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions...

Related Keywords

United Kingdom , United States , Ukraine , Bedford , Massachusetts , Cambridge , Cambridgeshire , Edwardm Kaye , Joseph Sullivan , Drug Administration , Company Annual Report On Form , Nasdaq , University Of California San Francisco , Stoke Therapeutics Inc , Augmentation Of Nuclear Gene Output , Pediatric Epilepsy Center , Exchange Commission , Stoke Therapeutics , Chief Executive Officer , California San Francisco , Study Results , Sustained Reductions , Convulsive Seizure , Convulsive Seizure Frequency , After Last Dose , Label Extension Studies , Vineland Adaptive Behavior Scale , Suspected Unexpected Serious Adverse Reactions , Conference Call , United Kingdom Studies , American Epilepsy Society , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Middle East , Annual Report , Markets ,